| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_abaede66a124010a58d8a6b950bd3d04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d53ef07847acec40515e0ac833eb1a3a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate |
2005-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f19b29151037ef6c617a317300f1d378 |
| publicationDate |
2005-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2005123053-A2 |
| titleOfInvention |
Use of cb2 receptors agonists for the treatment of huntington’s disease |
| abstract |
The present invention relates to ligands of the peripheral cannabinoid receptor CB2 especially (+)-α-pinene derivatives, and to pharmaceutical compositions comprising these compounds, and to the use of such compounds for treatment and prevention of the onset of genetic neurodegenerative disorders, in particular Huntington’s disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2030615-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8029815-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9526707-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008001369-A1 |
| priorityDate |
2004-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |